ムラガキ ヨシヒロ   MURAGAKI Yoshihiro
  村垣 善浩
   所属   研究施設 研究施設
   職種   教授
言語種別 英語
発表タイトル First-in-human Clinical Trial of Sonodynamic Therapy with Drug Delivery System
会議名 5th COINS Symposium Shaping a dream! In-body hospitals -Future hearth care created by Kawasaki ventures-
発表形式 ポスター掲示
発表者・共同発表者◎HORISE Yuki, OKAMOTO Jun, KONISHI Yoshiyuki, TAKEMAE,Kazuhisa Kazuhisa, KUSUDA Kaori, IZUMI Mikio , IKUTA Soko, MASAMUNE Ken, ISEKI Hiroshi, NISHIYAMA Nobuhiro , KATAOKA Kazunori, MURAGAKI Yoshihiro
発表年月日 2018/12/14
開催地
(都市, 国名)
Kawasaki
学会抄録 5th COINS Symposium 47
概要 Sonodynamic therapy (SDT) uses a chemical sonosensitizer in combination with high-
intensity focused ultrasound (HIFU), and it would reduce the reduction of drug dose and HIFU
irradiation power compared to those of conventional monotherapies. From our previous study
of four pet dogs with spontaneous tumors including osteosarcoma, hepatocellular cancer, and
prostate cancer, the usefulness of SDT using an anticancer micelle (NC-6300) was confirmed.
Based on the results, a clinical study involving the application of SDT method in humans was
recently conducted at Tokyo Medical University. SDT method was used to treat human patients
with unresectable, intractable cancers, such as pancreatic and biliary tract cancer, to evaluate
its safety under set fixed conditions, including the dosage of NC-6300 and the output power of
HIFU irradiation. While continuing a research into clarifying the action mechanism of this SDT
approach such as radical oxygen, we plan to conduct an investigator-initiated clinical trial to
evaluate the efficacy of SDT. This therapy has the potential to become a standard therapy and
contribute to the treatment of both pet and human cancers.